* Milestone Pharmaceuticals Inc MIST.OQ reported a
quarterly
adjusted loss of 37 cents per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of 39 cents per share.
* Reported revenue was zero; analysts expected zero.
* Milestone Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 37 cents.
* The mean earnings estimate of analysts had risen by
about 4% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Milestone Pharmaceuticals Inc shares had risen by 9.5%
this
quarter and lost 21.2% so far this year.
* The company reported a quarterly loss of $16.04 million.
* Wall Street's median 12-month price target for Milestone
Pharmaceuticals Inc is $13.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
August 10 at 02:16 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2023 -0.39 -0.37 Beat
Mar. 31 2023 -0.40 -0.35 Beat
Dec. 31 2022 -0.33 -0.31 Beat
Sep. 30 2022 -0.41 -0.34 Beat